Oncosec (ONCS) Announces Pact with Merck (MRK) to Evaluate Combination of ImmunoPulse IL-12 and KEYTRUDA for Metastatic Melanoma

May 10, 2017 7:55 AM EDT Send to a Friend
OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, has entered a clinical trial collaboration and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login